The 5-HTTLPR polymorphism was assessed as previously described by this laboratory.
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Figure 1 TPQ Novelty Seeking scores grouped by homozygosity at the DRD3 BalI restriction site. TPQ Novelty Seeking scores and D3DR BalI genotypes were inventoried for 32 previously studied heroin addicts. 7 porter polymorphism were collapsed (short/short & short/long vs long/long) as originally suggested by Lesch. 5 We also failed to observe an association between 5-HTTLPR and Harm Avoidance (one way ANOVA: F = 0.238, P = 0.789, d.f. = 2,39) in a small group of 42 heroin addicts for whom we had TPQ scores. This group had previously been studied and showed significantly higher Harm Avoidance scores than a matched control group. 7 Neither the BalI D3DR of 5-HTTLPR polymorphisms appear to contribute directly to opioid abuse. A role for these two genes in modifying the clinical characteristics of drug addiction is perhaps suggested by several recent studies 3, 4 but the number of subjects examined and the case control design employed advise caution in their interpretation. Family-based association studies such as the haplotype relative risk design as well as larger case control samples and additional inventorying of more common polymorphisms across ethnic and population divisions, will likely resolve the reasons for our apparent failure to validate early findings.
SNPs and polygenic disorders: a less gloomy view
SIR -The recent article in Science entitled A closer look at SNPs suggests difficulties, 1 reported presentations at a Swedish meeting that cast a gloomy view on the use of SNPs for identifying disease associations. The presentations pointed out that for the lipoprotein lipase gene there had been almost as much recombination as mutation, SNPs were unable to identify the role of the ␤-globin mutation in sickle cell disease, and more than 90% of the new disease genes reported in the American Journal of Human Genetics during the past 1.5 years had more than 10 disease-producing mutations. This difficulty is analogous to that of diagnosing single gene disorders by PCR testing for mutations. For example, a sampling of some of the most intensively studied genes, such as the Duchenne muscular dystrophy, breast cancer-1, and cystic fibrosis genes, show that there are so many diseasecausing mutations that this diagnostic task is a daunting one. It should come as no surprise that attempting to identify these mutations indirectly, by finding an association with random SNPs, would be even more difficult. Thus, I would agree that if all the human diseases were due to single gene mutations, this skepticism would be justified. However, less than 1% of human disease is due to single gene disorders. The purpose of developing SNPs is to identify the genes involved in the far more common and important polygenic disorders. I have suggested elsewhere 2, 3 that the genetic variants involved in polygenic disorders are likely to be fundamentally different from those involved in single gene disorders. For the sake of discussion I will term the mutations associated with single gene disorders-single gene variants (SGVs), and those associated with polygenic disorders-polygenic gene variants (PGVs). The most obvious difference between the two is that SGVs cause such severe disruption in gene function that only one is required to cause disease. By contrast, PGVs cause such a mild disruption in gene function that many of them must be added together to pass a threshold to cause disease. 4 A second, equally obvious difference is that SGVs are rare since single-gene disorders are rare, while PGVs must be very common, since polygenic disorders are common and multiple PGVs are required to produce them. For example, for a polygenic disorder occurring in 3% of the population and caused by the additive presence of five different PGVs, each having an equal effect, each PGV must be present in 50% of the population (0.5 × 0.5 × 0.5 × 0.5 × 0.5 = 0.03). How can PGVs be so common? I have suggested 3 that the minisatellites and miscrosatellites that are so common in the genome may play an important role in gene regulation because most of them are associated with Z-DNA. Z-DNA is an important alternate form of DNA that exposes the bases to interaction with nuclear proteins. 5 Many studies have shown that Z-DNA modulates gene function. 3 Since different length alleles of the repeat polymorphisms are associated with different lengths of Z-DNA, these alleles would be associated with moderate increases or decreases in the expression of the genes they are near. The effects of minisatellites on gene function have been shown to extend over considerable distances. 6 This carries the implication that the size of the minisatellite alleles, rather than any single mutant allele, is the most important variable for phenotype association studies. We have found this to be the case for microsatellites associated with a wide range of genes: (ADRA1C, ADRA2C, AR, CD4, CD8, CHRNA4,  CNR1, DBH, DRD4, DRD5, DAT1, ESRA, FRAXA,  GABRA1, GABRA3, GABRA5, GABBR1, GABRB3,  GABBR, GAD2, HTR1A, INFG, INS, MAOA, MAOB,  MC3R, NOS1A, NOS2A, OB1875, OB1871, PENK, TH,  TDO2) . Common SNPs which have a moderate effect on gene function can also be PGVs.
The important implication from the above is that the emphasis in the past century on single gene disorders has tended to produce the concept of a 'normal' gene whose function is occasionally interrupted by a few rare sequence variants in exons or promoters that result in a loss of function. If the minisatellite/common PGV-SNP hypothesis is correct there may instead be no such thing as a 'normal' gene, but rather a wide range of gene expression from hyper-to hypo-function. This concept is illustrated in Figure 1 , showing the SGV monogene vs the PGV polygene model. If correct, the polygene model has significant implications for the study of polygenic disorders. First, in the monogene model, it would be extremely unlikely that any common, random SNP would happen to occur on the same chromosome and only on the same chromosome, and thus be in linkage disequilibrium with a given SGV. As a result, it would be almost impossible for association studies using random SNPs to identify the genes involved in a single-gene disease-thus, the pessimism expressed in the Sweden conference. Combining multiple SNPs into haplotypes would not appreciably improve the results. By contrast, in polygenic disorders, at any given gene almost all of the chromosomes carry either a hypo-or a hyper-functional allele that can play a role in a polygenic disorder. As a result, virtually any random SNP would be in linkage disequilibrium with a hypo-or hyper-functional minisatellite variant. With bi-allelic SNPs the likelihood that the function of the gene would vary across the three 11, 12 and 22 genotypes would be very high. Now, arranging multiple SNPs into haplotypes would further improve the separation between these common hypo-and hyper-functional variants.
Second, at least in behavior genetics, the concept of a given gene being associated with phenotype A, but not phenotype B, may need revision. For example, an SNP 1 allele in linkage disequilibrium with a minisatellite allele causing a decrease in function of the gene may be associated with phenotype A, while the 2 allele of the same SNP may be in linkage disequilibrium with a minisatellite allele causing an increase in function and be associated with phenotype B. Thus, the SNP 1 allele would be positively associated with phenotype A and negatively associated with phenotype B, and vice versa. When the additive effect of genes is examined both genes would be important for both phenotypes.
Thus, in contrast to the gloomy outlook on SNPs portrayed in the Science report, when used as intended, to identify the genes associated with polygenic rather than single-gene disorders, SNPs will be very valuable. Since polygenic disorders are due to the additive effect of multiple PGVs, studies that examine the additive effect of SNPs at multiple candidate genes should provide a particularly powerful approach to studying polygenic disorders. 
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Phenotype definition and association studies in behavioral genetics
SIR -Case-control association studies investigating polymorphisms of candidate genes in behavioral disorders have produced many positive and negative findings with few consistent replications. [1] [2] [3] The inconsistent results of association studies in behavioral genetics are usually explained by the fact that significant-appearing relationships may be found as an artifact of genetic differences between the cases and controls because population stratification (or admixture), due to ethnic variation or other confounding factors, can generate considerable population differences in marker allele frequencies. It has been proposed that family-based studies which compare cases with relatives can eliminate such artifacts. 4, 5 Differences in polymorphism frequencies across ethnic groups and other population biases may have substantial effects on the results of association studies. However, a major problem of association studies in psychiatric genetics is that psychiatric diagnoses are not biologically real disease entities. Syndromal psychiatric diagnostic categories such as depression or schizophrenia include etiologically, pathologically, and prognostically heterogeneous disorders. 6 The broad categorical classification of behavioral disorders that is used in psychiatry at the present time is not suitable for genetic association studies. At present psychiatric phenotypes are so broad that we cannot establish the defining relationship between the behavior and the genes.
Extensive clinical research and observations are necessary to classify heterogeneous diagnostic categories such as depression or schizophrenia into more scientific and more homogenous disease entities. Certain subtypes of depression such as anxious depression, seasonal affective disorder, and postpartum depression have already been described. 7 However, much more work needs to be done.
Better definition of the phenotype can enhance the chance of detecting significant associations. Success in genetic research will depend on examining more homogenous and more narrowly defined phenotypes. 
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